Stock Analysis on Net

Cytokinetics Inc. (NASDAQ:CYTK)

$22.49

This company has been moved to the archive! The financial data has not been updated since November 3, 2023.

Cash Flow Statement

The cash flow statement provides information about a company cash receipts and cash payments during an accounting period, showing how these cash flows link the ending cash balance to the beginning balance shown on the company balance sheet.

The cash flow statement consists of three parts: cash flows provided by (used in) operating activities, cash flows provided by (used in) investing activities, and cash flows provided by (used in) financing activities.

Paying user area


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Cytokinetics Inc., consolidated cash flow statement

US$ in thousands

Microsoft Excel
12 months ended: Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
Net loss
Non-cash interest expense on liabilities related to revenue participation right purchase agreement
Stock-based compensation expense
Non-cash lease expense
Impairment of right-of-use assets
Depreciation of property and equipment
(Gain) loss on investment, net
Interest receivable and amortization on investments
Non-cash interest expense related to debt
Loss on extinguishment of debt
Loss on inducement of convertible debt
Accounts receivable
Contract assets
Prepaid and other assets
Accounts payable
Accrued and other liabilities
Contract liabilities
Deferred revenue
Operating lease liabilities
Other non-current liabilities
Changes in operating assets and liabilities
Adjustments to reconcile net loss to net cash provided by (used in) operating activities
Net cash provided by (used in) operating activities
Purchases of investments
Maturities of investments
Sales of investments
Purchases of property and equipment
Sales of property and equipment
Net cash (used in) provided by investing activities
Repayment of finance lease liabilities
Repayment of term loan
Debt extinguishment costs
Repayment of convertible debt
Proceeds from issuance of convertible debt, net
Proceeds from public offerings of common stock, net of discounts, commissions and offering cost
Proceeds from private placement, net
Proceeds from 2022 RPI Transactions, net
Proceeds from issuance of common stock under equity incentive and stock purchase plans
Taxes paid related to net share settlement of equity awards
Claims settlement under Section 16(b)
Cash settlement of capped call options associated with 2026 Notes
Net proceeds from long-term debt, net of debt discount and issuance costs
Issuance of common stock under at-the-market offering, net of issuance costs
Purchase of capped call options associated with convertible notes
Net cash provided by financing activities
Net increase (decrease) in cash, cash equivalents, and restricted cash equivalents
Cash, cash equivalents, and restricted cash equivalents, beginning of period
Cash, cash equivalents, and restricted cash equivalents, end of period

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).


Net Loss Trend
The net loss has shown a steady and significant increase over the five-year period, worsening from -$106.3 million in 2018 to -$389.0 million in 2022. The most notable escalations occurred between 2020 and 2021, and again into 2022, indicating rising operational or other expenses outpacing revenue or cost controls.
Non-Cash Expenses
Interest Expense Related to Revenue Participation Rights
This non-cash interest expense rose from $17.8 million in 2018, peaking at $31.9 million in 2022 after a drop in 2021, suggesting fluctuating liabilities related to revenue participation agreements.
Stock-Based Compensation
Increased substantially from $9.8 million in 2018 to $47.9 million in 2022, reflecting a growing reliance on equity incentives, potentially to attract or retain employees.
Depreciation and Lease Expenses
Depreciation of property and equipment more than quadrupled from $1.2 million to $5.8 million over the period. Non-cash lease expenses showed volatility, peaking in 2021 at $7.4 million, then dropping to $2.6 million in 2022. An impairment of right-of-use assets of $2.8 million was recorded in 2021.
Investments and Related Gains/Losses
Investment Gains/(Losses)
Net gains on investments were recorded only in 2020 (-$0.6 million loss) and a small gain of $0.1 million in 2022, indicating limited gains or losses on investment assets.
Interest Receivable and Amortization on Investments
Figures fluctuated widely, with negative amounts in most years except 2021, where a positive $4.9 million was recorded, showing variability in income or amortization related to investments.
Investment Purchases and Maturities
Purchases escalated each year from $240.2 million in 2018 to $855.4 million in 2022, while maturities also increased substantially, from $246.2 million to $604.6 million in the same timeframe, indicating active portfolio management with growing scale.
Working Capital and Related Items
Accounts Receivable and Contract Assets
Accounts receivable values oscillated significantly with a drastic negative to positive swing in 2021 and 2022, reflecting volatility or restructuring. Contract assets were reported positively in 2018 and 2019 but absent thereafter.
Prepaid and Other Assets
Consistently negative and worsening over the years, moving from $1.8 million in 2018 to -$7.4 million in 2022, suggesting increased prepayments or asset write-downs.
Accounts Payable and Accrued Liabilities
Accounts payable flipped from negative to positive and rose over the period, indicating variability in payables management. Accrued and other liabilities turned substantially positive from 2020 onward, suggesting increased accrued expenses or obligations.
Deferred Revenue and Contract Liabilities
Deferred revenue and contract liabilities showed irregular entries, with stark values such as $87 million deferred revenue recorded in 2020 and negative $87 million in 2022, also a large contract liabilities figure in 2018, implying volatile revenue recognition or contract accounting treatments.
Operating Lease Liabilities and Other Non-current Liabilities
Operating lease liabilities showed a large increase in 2021 at $43.5 million and then sharply decreased in 2022. Other non-current liabilities were reported only in 2021 and 2022 with opposing signs, suggesting changes in long-term obligations.
Cash Flows from Operating Activities
Net cash used in operating activities fluctuated considerably, including large negative cash flows in 2018, 2019, 2021, and 2022, with a brief positive inflow in 2020. Adjustments to reconcile net loss to operating cash were notably high in 2020, 2021, and 2022, indicating significant non-cash expenses affecting net loss but not cash flow directly.
Cash Flows from Investing Activities
Investing cash flows were predominantly negative, reflecting heavy investments in securities and property and equipment. Purchases of investments rose sharply with a large jump in 2022. Sales and maturities of investments partially offset purchases but did not suffice to generate positive investing cash flows in most years.
Cash Flows from Financing Activities
Financing cash inflows increased substantially, peaking at $516.2 million in 2022. This was driven by proceeds from convertible debt issuance, public offerings, private placements, revenue participation transactions, and equity issuance under stock plans. Debt repayments and repayment of finance leases became significant in 2022.
Cash Position
Cash and equivalents decreased sharply in 2018 and 2019, recovered strongly in 2020 and 2021, and dropped again in 2022. The end-period cash balance showed volatility, reflecting the net impact of operating, investing, and financing cash flows and highlighting periods of liquidity management challenges.